Where membranous nephropathy treatment is heading
Membranous nephropathy · Updated Nov 14, 2026
Membranous nephropathy is an autoimmune kidney disease and the most common cause of nephrotic syndrome (heavy protein loss in the urine, swelling and high clotting risk) in adults; a few thousand Americans are diagnosed each year. In most cases antibodies against the PLA2R protein on kidney filter cells drive the disease, and a blood test for them can track it. About a third of people improve on their own; others need rituximab, cyclophosphamide with steroids, or calcineurin inhibitors. In 2026 obinutuzumab beat tacrolimus in a phase 3 trial, and several more antibodies are in phase 3.
- 71studies open or running
- 14phase 3 trials
- 475papers published this year
- 23NIH-funded projects
-
Now
Nov 2026
Obinutuzumab beats tacrolimusHappened 37% complete remission
Complete remission at 2 years: 37% with obinutuzumab vs 6% with tacrolimus.
37%: in complete remission at 2 years, vs 6% with tacrolimus.
Rituximab and cyclophosphamide are comparableHappened 0.85 risk ratio (similar)
Across 11 studies, remission rates were similar (risk ratio 0.85).
0.85: risk ratio for remission at 12 months (not significant).
Targeting plasma cellsHappened 76.9% antibody response
Felzartamab halved anti-PLA2R antibodies in 76.9%, but one course did not help rituximab-resistant disease.
76.9%: with at least a 50% drop in anti-PLA2R antibodies.
-
6 months
by May 2027
Obinutuzumab in guidelinesPossible 37% complete remission
MAJESTY is likely to shape guidelines and could support an approval application.
37%: in complete remission at 2 years, vs 6% with tacrolimus.
-
12 months
by Nov 2027
A BTK inhibitorPossible
BeOne's ALMOND (178 people) compares zanubrutinib with tacrolimus; due October 2027.
ACTH gel vs rituximabLong shot
Cerium's SNP-ACTH trial (148 people) is due April 2027.
-
3 years
by late 2029
A dual BAFF/APRIL blockerPossible
Vertex's OLYMPUS (176 people) compares povetacicept with tacrolimus; due December 2028.
-
5 years
by late 2031
More antibodies head to headPossible 76.9% antibody response (felzartamab)
Biogen's felzartamab PROMINENT (due January 2030) and Amgen's inebilizumab MOMENT (due September 2031) each compare against tacrolimus.
76.9%: with at least a 50% drop in anti-PLA2R antibodies.
Cell therapy for refractory diseaseLong shot
CAR-NK cells and other cell therapies are in early trials.
The research paths
B-cell antibodies
37% complete remissionDetails and 3 trialsHide
Obinutuzumab, inebilizumab and anti-CD19 antibodies that deplete B cells more deeply than rituximab.
WatchMOMENT; budoprutug.
Plasma-cell and BAFF/APRIL targeting
76.9% antibody responseDetails and 2 trialsHide
Drugs aimed at the long-lived cells that keep making PLA2R antibodies.
WatchPROMINENT; OLYMPUS.
Pills and other approaches
70% antibody clearanceDetails and 4 trialsHide
BTK inhibitors, complement blockers, ACTH and combinations.
WatchALMOND.
Borrowed from other conditions
From CLL and lupus nephritis
Obinutuzumab
Phase 3
A type II anti-CD20 antibody approved for lymphoma and lupus nephritis.
From Neuromyelitis optica
Inebilizumab
Phase 3
An anti-CD19 antibody approved for NMOSD.
From B-cell lymphomas
Zanubrutinib
Phase 3
A BTK inhibitor approved for several lymphomas.
Open to join now
-
Primary membranous nephropathy
Felzartamab
Locations and eligibility → -
Primary membranous nephropathy
Povetacicept
Locations and eligibility → -
Primary membranous nephropathy
Inebilizumab
Locations and eligibility → -
Primary membranous nephropathy
Budoprutug
Locations and eligibility →
See every recruiting Membranous nephropathy trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
Obinutuzumab beats tacrolimus for complete remission
MAJESTY, NEJM.
Felzartamab course fails in rituximab-resistant disease
Kidney Int Rep.
Standard treatment today
- Low riskSupportive care (ACE inhibitor or ARB, diuretics, statins) and monitoring of PLA2R antibodies.
- Moderate or high riskRituximab, or cyclophosphamide with steroids, or a calcineurin inhibitor; obinutuzumab increasingly used.
- Very high risk or refractoryCyclophosphamide with steroids, combined regimens, or clinical trials.
- Heavy nephrotic syndromeBlood thinners to prevent clots in selected patients.
How to read this page, and sourcesHow to read this page, and sources
- Membranous nephropathy can also be caused by lupus, infections, drugs or cancer; this page focuses on primary (autoimmune) disease.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See Membranous nephropathy trials recruiting now →